Treatment interruption trials are a vital tool, but their optimal design remain uncertain and
must balance participant risks with scientific rigor. The ability to predict the timing or extent of
HIV rebound and identify mechanisms of posttreatment control may accelerate the
development of novel therapeutics for sustained HIV remission.